Bibliography: library/10665-97885

The reference for library/10665-97885 (who-iris) and any references extracted from it. library · All references.

Export these 101 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

101 shown

  1. Mclean, Huong Q; Hickman, C. J; Seward, Jane F; et al. (2010). The immunological basis for immunization series: module 16: mumps. World Health Organization.
    10665-97885 · catalogue · link · repository record · ISBN 9789241500661 · source: catalogue/records/10665-97885.dc.json · held: library/10665-97885
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Jeryl Lynn/RIT 4385 (Fescharek et al., 1990) ~5 500 000 Drug side-effect surveillance 0.1 (Schlipkoter et al., 2002) 1 575 936 National hospital surveillance system <0.2 (Miller et al., 2007) >99 000 (Black et al., 1997)
    · extracted · source: references/10665-97885.sec-006.1.json
  3. United States ~300 000 Urabe Am 9 (Al-Mazrou et al., 2002)
    · extracted · source: references/10665-97885.sec-006.2.json
  4. Saudi Arabia 2 412 078 6–13 years* National, hospital, and school surveillance 0.3 (Jonville-Bera et al., 1996) 11 months – 10 years Reports to regional pharmacovigilance centres or manufacturer 0.82 0.77– 0.92)
    · extracted · source: references/10665-97885.sec-006.3.json
  5. Canada 250 000-300 000 Laboratory reports 1.6 (Rebiere & Galy-Eyraud, 1995) 3 290 470 (mostly <24 months)
    · extracted · source: references/10665-97885.sec-006.5.json
  6. Vaccine manufacturer’s surveillance system and laboratory surveillance 3.5 1.5–5.6) (Farrington et al., 1995)
    · extracted · source: references/10665-97885.sec-006.6.json
  7. England 77 200 6.7 (Dourado et al., 2000) 452 344 State surveillance and prospective hospital admission following mass-vaccination campaign 7.1 (Miller et al., 2007) 49 585 8.0 2.2–21)
    · extracted · source: references/10665-97885.sec-006.7.json
  8. (Sugiura & Yamada, 1991) 630 157 Passive surveillance to Ministry of Health 12–15 (Miller et al., 1993) 78 300 Public Health Laboratories and hospital discharge diagnosis (Colville & Pugh, 1992) 22 817 Laboratory records 5.3–47)
    · extracted · source: references/10665-97885.sec-006.8.json
  9. (Fujinaga et al., 1991) 11 750 Hospital surveillance (Ueda et al., 1995)
    · extracted · source: references/10665-97885.sec-006.9.json
  10. Leningrad 3 (Cizman et al., 1989)
    · extracted · source: references/10665-97885.sec-006.10.json
  11. Yugoslavia 115 253 L-Zagreb (Pan American Health Organization, 1999)
    · extracted · source: references/10665-97885.sec-006.11.json
  12. Bahamas >100 000 4–40 years Surveillance activities not mentioned (note: small proportion of doses were Jeryl Lynn mumps strain) 0.96 (Phadke et al., 2004)
    · extracted · source: references/10665-97885.sec-006.12.json
  13. India 190 723 Post-marketing surveillance surveys to paediatricians (note: response rate 68%) 1.0 (da Cunha et al., 2002) 845 889 Children† Routine surveillance system and hospital records 5.2–16 (Arruda & Kondageski, 2001) 590 609 2–39 years National surveillance (da Silveira et al., 2002) 110 629 Passive surveillance (Dos Santos et al., 2002) 2 226 6–12 years Active follow-up (Tesovic & Lesnikar, 2006) 96 994 12–46 months Prospective hospital study 36–66)
    · extracted · source: references/10665-97885.sec-006.13.json
  14. (Tesovic et al., 1993) 10 months–6 years 64–116)
    · extracted · source: references/10665-97885.sec-006.14.json
  15. Hoshino (Kimura et al., 1996) 21 717 (Ueda et al., 1995) * Probable second dose. † Campaign dose, irrespective of prior vaccination history.
    · extracted · source: references/10665-97885.sec-006.17.json
  16. L-Zagreb (Pan American Health Organization, 1999)
    · extracted · source: references/10665-97885.sec-006-2.1.json
  17. Bahamas >100 000 4–40 years Surveillance activities not mentioned (note: small proportion of doses were Jeryl Lynn mumps strain) 0.96 (Phadke et al., 2004)
    · extracted · source: references/10665-97885.sec-006-2.2.json
  18. India 190 723 Post-marketing surveillance surveys to paediatricians (note: response rate 68%) 1.0 (da Cunha et al., 2002) 845 889 Children† Routine surveillance system and hospital records 5.2–16 (Arruda & Kondageski, 2001) 590 609 2–39 years National surveillance (da Silveira et al., 2002) 110 629 Passive surveillance (Dos Santos et al., 2002) 2 226 6–12 years Active follow-up (Tesovic & Lesnikar, 2006) 96 994 12–46 months Prospective hospital study 36–66)
    · extracted · source: references/10665-97885.sec-006-2.3.json
  19. (Tesovic et al., 1993) 10 months–6 years 64–116)
    · extracted · source: references/10665-97885.sec-006-2.4.json
  20. Hoshino (Kimura et al., 1996) 21 717 (Ueda et al., 1995) * Probable second dose. † Campaign dose, irrespective of prior vaccination history.
    · extracted · source: references/10665-97885.sec-006-2.7.json
  21. Median Range 95.9 74.2, 99.6 (Weibel et al., 1967; Hilleman et al., 1968; Sugg et al., 1968; Brunell et al., 1969; Vesikari et al., 1983b; Fedova et al., 1987) 90.0 83.5, 90.6 (Weibel et al., 1973; Vesikari et al., 1983a; Popow-Kraupp et al., 1986) 89, 97 (Borgono et al., 1973; Ehrenkranz et al., 1975; Schwarz et al., 1975; Lerman et al., 1981; Popow-Kraupp et al., 1986; Schwarzer et al., 1998; Usonis et al., 1998; Usonis et al., 1999; Klinge et al., 2000; Redd et al., 2004; Feiterna-Sperling et al., 2005) tetravalent 99.5 98, 100 (Watson et al., 1996; Shinefield et al., 2005; Kuter et al., 2006; Bernstein et al., 2007)
    · extracted · source: references/10665-97885.sec-013.1.json
  22. RIT 4385, 96.4 88, 98.6 (Usonis et al., 1998; Gatchalian et al., 1999; Usonis et al., 1999; Crovari et al., 2000; Lee et al., 2002; Nolan et al., 2002; Stuck et al., 2002; Lim et al., 2007) 94.8 82.6, 97 (Isomura et al., 1973; Ehrengut et al., 1983; Vesikari et al., 1983b) 84.2 78.7, 96.9 (Vesikari et al., 1983a; Popow-Kraupp et al., 1986) 96.9, 100 (Berger et al., 1988; Robertson et al., 1988; Dunlop et al., 1989; Schoub et al., 1990; Forleo-Neto et al., 1997)
    · extracted · source: references/10665-97885.sec-013.2.json
  23. Rubini 93.3 23.3, 95 (Gluck et al., 1986; Just et al., 1986; Berger et al., 1988; Schwarzer et al., 1998; Khalil et al., 1999; Crovari et al., 2000)
    · extracted · source: references/10665-97885.sec-013.3.json
  24. Leningrad-3 93.5 89, 98 (Smorodintsev et al., 1970)
    · extracted · source: references/10665-97885.sec-013.4.json
  25. Leningrad-Zagreb 89.4 88.1, 90.7 (Beck et al., 1989)
    · extracted · source: references/10665-97885.sec-013.5.json
  26. BBM-18 84.8 (Feiterna-Sperling et al., 2005)
    · extracted · source: references/10665-97885.sec-013.6.json
  27. Sofia 6 93.4 92.6, 94.1 (Odisseev & Gacheva, 1994)
    · extracted · source: references/10665-97885.sec-013.7.json
  28. Hoshino 98.4 96.8, 100 (Makino et al., 1990)
    · extracted · source: references/10665-97885.sec-013.8.json
  29. S-12 (Sassani et al., 1991) 3.2 Immune responses to revaccination Studies have examined presence of antibodies prior to and following the second dose of mumps vaccine. In a prospective study, <1% of subjects were seronegative before a second dose of mumps vaccine and, following the second dose, IgM was detectable in only 2% of individuals, suggesting that most vaccine recipients had mounted a secondary immune response to revaccination (LeBaron et al., 2009). Although up to 30% of individuals were reported to be seronegative prior to revaccination in other studies, 75% to 97% seroconverted following the second dose of mumps vaccine.
    · extracted · source: references/10665-97885.sec-013.9.json
  30. There was no assessment to determine if seronegativity was due to primary vaccine failure, or having antibody below the level of test detection (Broliden et al., 1998; Gothefors et al., 2001).
    · extracted · source: references/10665-97885.sec-013.10.json
  31. Among individuals with neutralizing antibodies prior to receipt of a second dose, an increase in antibody levels generally occurred following revaccination. More than 50% of those revaccinated had a four-fold increase in antibody titres (LeBaron et al., 2009). In addition, the proportion of individuals with low titres was significantly reduced.
    · extracted · source: references/10665-97885.sec-013.11.json
  32. Country Years after vaccination Number seropositive/Number tested (%) Serological method used 1 dose (LeBaron et al., 2009) 304/308 (99)
    · extracted · source: references/10665-97885.sec-015.1.json
  33. (Gothefors et al., 2001) ~10 230/299 (70)
    · extracted · source: references/10665-97885.sec-015.2.json
  34. (Broliden et al., 1998) ~11 167/229 (73)
    · extracted · source: references/10665-97885.sec-015.3.json
  35. Neutralizing antibodies 2 doses (LeBaron et al., 2009) 17/189 (91)
    · extracted · source: references/10665-97885.sec-015.4.json
  36. (Date et al., 2008) ≥11 134/146 (92)
    · extracted · source: references/10665-97885.sec-015.5.json
  37. (LeBaron et al., 2009) 146/154 (95)* (Davidkin et al., 2008)
    · extracted · source: references/10665-97885.sec-015.6.json
  38. Finland 67/90 (74) * All subjects were seropositive prior to receipt of second mumps vaccine. The immunological basis for immunization series - Module 16: Mumps In two-dose recipients, mumps antibodies were detectable in 95% and 74% of children 12 and 15 years after receipt of a second dose of MMR, respectively, but antibody levels declined with time (Table 3) (Davidkin et al., 2008; LeBaron et al., 2009).
    · extracted · source: references/10665-97885.sec-015.7.json
  39. The significance and function of mumps-specific CMI in protection against mumps disease has yet to be determined. Finally, the role of external boosting from exposure to wild mumps virus in maintaining immunity has not been studied.
    · extracted · source: references/10665-97885.sec-015.9.json
  40. Jeryl Lynn — one dose (Chamot et al., 1998) 62 (95% CI: 0, 85)
    · extracted · source: references/10665-97885.sec-023.1.json
  41. (Harling et al., 2005) 64 (95% CI: 40, 78)
    · extracted · source: references/10665-97885.sec-023.2.json
  42. (Toscani et al., 1996) 65 (95% CI: 11, 86)
    · extracted · source: references/10665-97885.sec-023.3.json
  43. (Castilla et al., 2009) 66 (95% CI: 25, 85)
    · extracted · source: references/10665-97885.sec-023.5.json
  44. Population (young children) 70 (95% CI: 50, 80) (Lewis et al., 1979)
    · extracted · source: references/10665-97885.sec-023.7.json
  45. Canada (Wharton et al., 1988) 78 (95% CI: 65, 86)
    · extracted · source: references/10665-97885.sec-023.8.json
  46. (Schlegel et al., 1999) 78 (95% CI: 64, 82)
    · extracted · source: references/10665-97885.sec-023.9.json
  47. United States Camp attendees and staff 80 (95% CI: 42, 93) (Sullivan et al., 1985) 81 (95% CI: 71, 88)
    · extracted · source: references/10665-97885.sec-023.11.json
  48. Child care centre and school 81 (95% CI: 58, 91) (Cheek et al., 1995) 82 (95% CI: 77, 86)
    · extracted · source: references/10665-97885.sec-023.13.json
  49. (Marin et al., 2008) 82 (95% CI: 0, 98)
    · extracted · source: references/10665-97885.sec-023.14.json
  50. (Hersh et al., 1991) 83 (95% CI: 57, 94)
    · extracted · source: references/10665-97885.sec-023.15.json
  51. (Kim-Farley et al., 1985) 85 (95% CI: 39, 94)
    · extracted · source: references/10665-97885.sec-023.16.json
  52. (Cohen et al., 2007)* 88 (95% CI: 83, 91)
    · extracted · source: references/10665-97885.sec-023.17.json
  53. (Chaiken et al., 1987) 91 (95% CI: 77, 93)
    · extracted · source: references/10665-97885.sec-023.18.json
  54. Jeryl Lynn — two doses (Marin et al., 2008) 79 (95% CI: 0, 97)
    · extracted · source: references/10665-97885.sec-023.19.json
  55. (Castilla et al., 2009) 83 (95% CI: 54, 94)
    · extracted · source: references/10665-97885.sec-023.20.json
  56. (Harling et al., 2005)* 88 (95% CI: 62, 96)
    · extracted · source: references/10665-97885.sec-023.21.json
  57. United States Close contacts 88 (95% CI: 63, 96) (Sartorius et al., 2005)
    · extracted · source: references/10665-97885.sec-023.23.json
  58. United States Camp population 92 (95% CI: 83, 96) (Cohen et al., 2007)* 95 (95% CI: 93, 96)
    · extracted · source: references/10665-97885.sec-023.25.json
  59. Urabe Am 9 (Ong et al., 2005) 54 (95% CI: -16, 82)
    · extracted · source: references/10665-97885.sec-023.26.json
  60. (Goncalves et al., 1998) 70 (95% CI: 25, 88)
    · extracted · source: references/10665-97885.sec-023.27.json
  61. (Chamot et al., 1998) 73 (95% CI: 42, 88)
    · extracted · source: references/10665-97885.sec-023.28.json
  62. (Toscani et al., 1996) 76 (95% CI: 36, 91)
    · extracted · source: references/10665-97885.sec-023.29.json
  63. (Schlegel et al., 1999) 87 (95% CI: 76, 94)
    · extracted · source: references/10665-97885.sec-023.30.json
  64. Rubini (Pons et al., 2000) -340 (Ong et al., 2005) -55 (95% CI: -122, -9)
    · extracted · source: references/10665-97885.sec-023.31.json
  65. (Schlegel et al., 1999) -4 (95% CI: -218, 15)
    · extracted · source: references/10665-97885.sec-023.32.json
  66. (Goncalves et al., 1998) 1 (95% CI: -108, 53)
    · extracted · source: references/10665-97885.sec-023.33.json
  67. (Chamot et al., 1998) 6 (95% CI: -46, 40)
    · extracted · source: references/10665-97885.sec-023.34.json
  68. (Toscani et al., 1996) 12 (95% CI: -102, 62)
    · extracted · source: references/10665-97885.sec-023.35.json
  69. (Pons et al., 2000) 40 (95% CI: -66, 78)
    · extracted · source: references/10665-97885.sec-023.36.json
  70. The immunological basis for immunization series - Module 16: Mumps (Richard et al., 2003)
    · extracted · source: references/10665-97885.sec-023.37.json
  71. (young children) 30 (95% CI: -30, 60) (Paccaud et al., 1995) 50 (95% CI: -19, 81)
    · extracted · source: references/10665-97885.sec-023.38.json
  72. Leningrad-Zagreb (Beck et al., 1989)
    · extracted · source: references/10665-97885.sec-023.39.json
  73. Yugoslavia Pre-school 97-100 Leningrad-3 (Smorodintsev et al., 1965) 94 (95% CI: 76, 98)
    · extracted · source: references/10665-97885.sec-023.40.json
  74. S79 (Fu et al., 2008) 86 (95% CI: 77, 92)
    · extracted · source: references/10665-97885.sec-023.41.json
  75. (Fu et al., 2009) 83 (95% CI: 68, 91)
    · extracted · source: references/10665-97885.sec-023.42.json
  76. Sofia 6 (Odisseev & Gacheva, 1994) Bulgaria Contacts * Some of the study population may have received mumps vaccine containing RIT 4385 strain.
    · extracted · source: references/10665-97885.sec-023.43.json
  77. Although five of the six studies had higher vaccine effectiveness for two doses compared to one dose, only one study reached statistical significance, and this was probably due to the large sample size (Cohen et al., 2007). Despite relatively high two-dose vaccine effectiveness, high two-dose vaccine coverage may not be sufficient to prevent all outbreaks (Cortese et al., 2008; Dayan & Rubin, 2008).
    · extracted · source: references/10665-97885.sec-023.45.json
  78. A number of studies documented increased risk of developing mumps with increasing time after vaccination (Vandermeulen et al., 2004; Cortese et al., 2008; Castilla et al., 2009), and data from the United Kingdom indicates vaccine effectiveness may decrease with age, which probably also reflects increasing time from vaccination (Cohen et al., 2007).
    · extracted · source: references/10665-97885.sec-023.46.json
  79. (young children) 30 (95% CI: -30, 60) (Paccaud et al., 1995) 50 (95% CI: -19, 81)
    · extracted · source: references/10665-97885.sec-023-2.2.json
  80. Leningrad-Zagreb (Beck et al., 1989)
    · extracted · source: references/10665-97885.sec-023-2.3.json
  81. Yugoslavia Pre-school 97-100 Leningrad-3 (Smorodintsev et al., 1965) 94 (95% CI: 76, 98)
    · extracted · source: references/10665-97885.sec-023-2.4.json
  82. S79 (Fu et al., 2008) 86 (95% CI: 77, 92)
    · extracted · source: references/10665-97885.sec-023-2.5.json
  83. (Fu et al., 2009) 83 (95% CI: 68, 91)
    · extracted · source: references/10665-97885.sec-023-2.6.json
  84. Sofia 6 (Odisseev & Gacheva, 1994) Bulgaria Contacts * Some of the study population may have received mumps vaccine containing RIT 4385 strain.
    · extracted · source: references/10665-97885.sec-023-2.7.json
  85. Although five of the six studies had higher vaccine effectiveness for two doses compared to one dose, only one study reached statistical significance, and this was probably due to the large sample size (Cohen et al., 2007). Despite relatively high two-dose vaccine effectiveness, high two-dose vaccine coverage may not be sufficient to prevent all outbreaks (Cortese et al., 2008; Dayan & Rubin, 2008).
    · extracted · source: references/10665-97885.sec-023-2.9.json
  86. A number of studies documented increased risk of developing mumps with increasing time after vaccination (Vandermeulen et al., 2004; Cortese et al., 2008; Castilla et al., 2009), and data from the United Kingdom indicates vaccine effectiveness may decrease with age, which probably also reflects increasing time from vaccination (Cohen et al., 2007).
    · extracted · source: references/10665-97885.sec-023-2.10.json
  87. Afzal MA et al. (1993). The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. The Journal of General Virology, 74 (Pt. 5):917–920.
    · extracted · source: references/10665-97885.sec-024.1.json
  88. Al-Mazrou Y et al. (2002). Safety evaluation of MMR vaccine during a primary school campaign in Saudi Arabia. Journal of Tropical Pediatrics, 48(6):354–358.
    · extracted · source: references/10665-97885.sec-024.2.json
  89. Arday DR et al. (1989). Mumps in the US Army 1980–86: should recruits be immunized? American Journal of Public Health, 79(4):471–474.
    · extracted · source: references/10665-97885.sec-024.3.json
  90. Arruda WO, Kondageski C (2001). Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Parana, Brazil, 1998. Revista do Instituto de Medicina Tropical de São Paulo, 43(5):301–302.
    · extracted · source: references/10665-97885.sec-024.4.json
  91. Association for the Study of Infectious Diseases (1974). A retrospective survey of the complications of mumps. The Journal of the Royal College of General Practitioners, 24(145):552–556.
    · extracted · source: references/10665-97885.sec-024.5.json
  92. Atrasheuskaya AV et al. (2006). Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine, 24(10):1530–1536.
    · extracted · source: references/10665-97885.sec-024.6.json
  93. Azimi PH et al. (1969). Mumps meningoencephalitis in children. JAMA : The Journal of the American Medical Association, 207(3):509–512.
    · extracted · source: references/10665-97885.sec-024.7.json
  94. Bang HO, Bang J (1943). Involvement of the central nervous system in mumps.
    · extracted · source: references/10665-97885.sec-024.8.json
  95. Acta medica scandinavica, 113:487–505. Beard CM et al. (1977). The incidence and outcome of mumps orchitis in Rochester, Minnesota, 1935 to 1974. Mayo Clinic Proceedings. Mayo Clinic, 52(1):3–7.
    · extracted · source: references/10665-97885.sec-024.9.json
  96. Beck M et al. (1989). Mumps vaccine L-Zagreb, prepared in chick fibroblasts.
    · extracted · source: references/10665-97885.sec-024.10.json
  97. I. Production and field trials. Journal of Biological Standardization, 17(1):85–90. Benito RJ et al. (1987). Persistence of specific IgM antibodies after natural mumps infection. The Journal of Infectious Diseases, 155(1):156–157.
    · extracted · source: references/10665-97885.sec-024.11.json
  98. Berger R et al. (1988). Interference between strains in live virus vaccines. I: Combined vaccination with measles, mumps and rubella vaccine. Journal of Biological Standardization, 16(4):269–273.
    · extracted · source: references/10665-97885.sec-024.12.json
  99. Bernstein HH et al. (2007). Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). Pediatrics, 119(6):e1299–e1305.
    · extracted · source: references/10665-97885.sec-024.13.json
  100. Bitnun S et al. (1986). Acute bilateral total deafness complicating mumps.
    · extracted · source: references/10665-97885.sec-024.14.json
  101. The Journal of Laryngology and Otology, 100(8):943–945.
    · extracted · source: references/10665-97885.sec-024.15.json